104 related articles for article (PubMed ID: 22326030)
1. In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: is this a new immediate-release therapeutic option for niacin?
Ledwidge MT; Ryan F; Kerins DM; O'Connell D; Cefali G; Harmon S; Jones M; Gilmer JF
Atherosclerosis; 2012 Apr; 221(2):478-83. PubMed ID: 22326030
[TBL] [Abstract][Full Text] [Related]
2. Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (ST0702) and aspirin.
Medina C; Harmon S; Inkielewicz I; Santos-Martinez MJ; Jones M; Cantwell P; Bazou D; Ledwidge M; Radomski MW; Gilmer JF
Br J Pharmacol; 2012 Jun; 166(3):938-49. PubMed ID: 22122360
[TBL] [Abstract][Full Text] [Related]
3. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
4. Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.
Aye MM; Kilpatrick ES; Afolabi P; Wootton SA; Rigby AS; Coady AM; Sandeman DD; Atkin SL
Diabetes Obes Metab; 2014 Jun; 16(6):545-52. PubMed ID: 24401089
[TBL] [Abstract][Full Text] [Related]
5. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a "true" aspirin prodrug.
Moriarty LM; Lally MN; Carolan CG; Jones M; Clancy JM; Gilmer JF
J Med Chem; 2008 Dec; 51(24):7991-9. PubMed ID: 19049433
[TBL] [Abstract][Full Text] [Related]
7. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
8. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
9. Isosorbide-based aspirin prodrugs: integration of nitric oxide releasing groups.
Jones M; Inkielewicz I; Medina C; Santos-Martinez MJ; Radomski A; Radomski MW; Lally MN; Moriarty LM; Gaynor J; Carolan CG; Khan D; O'Byrne P; Harmon S; Holland V; Clancy JM; Gilmer JF
J Med Chem; 2009 Nov; 52(21):6588-98. PubMed ID: 19821574
[TBL] [Abstract][Full Text] [Related]
10. Effect of colesevelam and niacin on low-density lipoprotein cholesterol and glycemic control in subjects with dyslipidemia and impaired fasting glucose.
Davidson MH; Rooney M; Pollock E; Drucker J; Choy Y
J Clin Lipidol; 2013; 7(5):423-32. PubMed ID: 24079283
[TBL] [Abstract][Full Text] [Related]
11. The in vitro effects of niacin on platelet biomarkers in human volunteers.
Serebruany V; Malinin A; Aradi D; Kuliczkowski W; Norgard NB; Boden WE
Thromb Haemost; 2010 Aug; 104(2):311-7. PubMed ID: 20539903
[TBL] [Abstract][Full Text] [Related]
12. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
13. Reversal of postprandial endothelial dysfunction by cyclooxygenase inhibition in healthy volunteers.
Signori LU; da Silva AM; Plentz RD; Moreno H; Irigoyen MC; Schaan BD
J Cardiovasc Pharmacol; 2009 Jul; 54(1):90-3. PubMed ID: 19546816
[TBL] [Abstract][Full Text] [Related]
14. Niacin-induced "flush" involves release of prostaglandin D2 from mast cells and serotonin from platelets: evidence from human cells in vitro and an animal model.
Papaliodis D; Boucher W; Kempuraj D; Michaelian M; Wolfberg A; House M; Theoharides TC
J Pharmacol Exp Ther; 2008 Dec; 327(3):665-72. PubMed ID: 18784348
[TBL] [Abstract][Full Text] [Related]
15. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance.
Linke A; Sonnabend M; Fasshauer M; Höllriegel R; Schuler G; Niebauer J; Stumvoll M; Blüher M
Atherosclerosis; 2009 Jul; 205(1):207-13. PubMed ID: 19131065
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
17. Niacin: a lipid polypill?
Kostner K; Gupta S
Expert Opin Pharmacother; 2008 Nov; 9(16):2911-20. PubMed ID: 18937622
[TBL] [Abstract][Full Text] [Related]
18. Human pharmacology of naproxen sodium.
Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
[TBL] [Abstract][Full Text] [Related]
19. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
20. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins.
Yuvaraj S; Premkumar VG; Vijayasarathy K; Gangadaran SG; Sachdanandam P
Clin Biochem; 2007 Jun; 40(9-10):623-8. PubMed ID: 17425952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
